Delcath Systems to Be Featured on "Health Uncensored with Dr. Drew" in Segment Highlighting Advances in Liver-Directed Cancer Treatment

"Precision Oncology: Changing the Game for Metastatic Liver Cancer" to air Sunday, November 15 at 5:30 p.m. ET / 2:30 pm PT on Fox Business

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the Company will be featured on Health Uncensored with Dr. Drew in a segment titled "Precision Oncology: Changing the Game for Metastatic Liver Cancer." The segment is scheduled to air nationally on Sunday, November 15, 2026. A podcast is also expected to be released following the television broadcast.

How to Watch

  • Program: Health Uncensored with Dr. Drew
  • Episode title: Mario & Courtney Lopez: Health From the Inside Out
  • Network: FOX Business Network
  • Air date: Sunday, November 15, 2026
  • Time: 5:30 p.m. ET / 2:30 pm PT

Episodes of Health Uncensored with Dr. Drew are also available following broadcast on HealthUncensoredTV.com and the show's YouTube channel.

The program includes a discussion of percutaneous hepatic perfusion (PHP), a liver-directed approach that delivers high-dose chemotherapy directly to the liver while filtering the blood before it is returned to systemic circulation, limiting systemic exposure. Delcath's Hepatic Delivery System is designed for use in this procedure. The program takes viewers inside a treatment center.

Gerard Michel, Chief Executive Officer of Delcath Systems, Inc. and Dr. Sachin Modi, Consultant Interventional Radiologist at University Hospital Southampton in the United Kingdom are both featured in the segment. Utilizing Delcath's Hepatic Delivery System, University Hospital Southampton has performed more than 500 PHP procedures.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT ™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) in the United States and CHEMOSAT ® Hepatic Delivery System for Melphalan in Europe, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure during a percutaneous hepatic perfusion procedure.

HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

For more information about Delcath Systems, Inc., visit the Company's website.

Important Safety Information

HEPZATO KIT carries a boxed warning for severe peri-procedural complications and myelosuppression and is available only through a restricted program under the HEPZATO KIT REMS. Severe peri-procedural complications, including hemorrhage, hepatocellular injury and thromboembolic events, may occur. Myelosuppression can result in severe infection, bleeding or symptomatic anemia.

Please see the full Prescribing Information, including Boxed Warning, for HEPZATO KIT .

Investor Relations
ICR Healthcare
investorrelations@delcath.com

News Provided by Business Wire via QuoteMedia

DCTH
The Conversation (0)
CleanTech Lithium PLC Announces Notice of AGM

CleanTech Lithium PLC Announces Notice of AGM

CleanTech Lithium PLC Notice of Annual General Meeting CleanTech Lithium PLC (AIM:CTL)(Frankfurt:T2N)(OTCQX:CTLHF) ("CleanTech Lithium" or the "Company"), an exploration and development company advancing sustainable lithium projects in Chile, will hold its Annual General Meeting ("AGM") at the... Keep Reading...
CleanTech Lithium PLC Announces Interim Results

CleanTech Lithium PLC Announces Interim Results

Interim Results for six-month period ending 30 June 2024 CleanTech Lithium PLC (AIM:CTL)(Frankfurt:T2N)(OTCQX:CTLHF), an exploration and development companyadvancing sustainable lithium projects in Chile for the clean energy transition, is pleased to announce its unaudited Interim Results for... Keep Reading...
CleanTech Lithium PLC Announces CEOL Update

CleanTech Lithium PLC Announces CEOL Update

Chilean Government prioritises Laguna Verde for CEOL CleanTech Lithium PLC (AIM:CTL)(Frankfurt:T2N)(OTCQX:CTLHF), an exploration and development company advancing lithium projects in Chile for the clean energy transition, reports an announcement by the Chilean Government on the Expressions of... Keep Reading...
CleanTech Lithium PLC Announces Community Support for Laguna Verde Project

CleanTech Lithium PLC Announces Community Support for Laguna Verde Project

Indigenous community leader publicly endorses Laguna Verde project at key mining seminar in Santiago, Chile CleanTech Lithium PLC (AIM:CTL)(Frankfurt:T2N)(OTCQX:CTLHF), an exploration and development company advancing sustainable lithium projects in Chile, participated in the Centre for Copper... Keep Reading...
CleanTech Lithium PLC Announces Transfer of Loan Notes at Regal Funds

CleanTech Lithium PLC Announces Transfer of Loan Notes at Regal Funds

CleanTech Lithium PLC (AIM:CTL)(Frankfurt:T2N)(OTCQX:CTLHF), an exploration and development company advancing sustainable lithium projects in Chile, announces the transfer of AUD Loan Notes (Loan Notes) from one Regal Funds1 associate to another Regal Funds associate On 1 July 2024, the Company... Keep Reading...

Interactive Chart

Latest Press Releases

Related News